Improving reconstituted HDL composition for efficient post-ischemic reduction of ischemia reperfusion injury

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Brulhart Meynet, Marie Claude ^a   Braunersreuther, Vincent ^b   Brinck, Jonas ^a   Montecucco, Fabrizio ^b,c   Prost, Jean Christophe ^d   Thomas, Aurelien ^d   Galan, Katia ^b   Pelli, Graziano ^b   Pedretti, Sarah ^e   Vuilleumier, Nicolas ^b   Mach, Franҫois ^b   Lecour, Sandrine ^e   James, Richard W ^a   Frias, Miguel A ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL1 CHEMOKINE; DOXORUBICIN; HIGH DENSITY LIPOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN KINASE B; SPHINGOSINE 1 PHOSPHATE; STAT3 PROTEIN; APOLIPOPROTEIN A1; LYSOPHOSPHOLIPID; MITOGEN ACTIVATED PROTEIN KINASE 1; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOVASCULAR RESPONSE; CELL DEATH; CELL SURVIVAL; EX VIVO STUDY; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART PROTECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPID PEROXIDATION; MALE; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RAT; REPERFUSION INJURY; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CARDIAC MUSCLE CELL; CELL CULTURE; DRUG EFFECTS; METABOLISM; MOUSE; MYOCARDIAL REPERFUSION INJURY; WISTAR RAT;

ANIMALS; APOLIPOPROTEIN A-I; CELLS, CULTURED; LIPOPROTEINS, HDL; LYSOPHOSPHOLIPIDS; MALE; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; SPHINGOSINE; STAT3 TRANSCRIPTION FACTOR;

EID: 84924975762     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119664     Document Type: Article

References (28)

1. Luscher TF, Landmesser U, von Eckardstein A, Fogelman AM. High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target. Circulation research. 2014; 114 (1):171-82. Epub 2014/01/05. doi: 10.1161/CIRCRESAHA.114.300935 PMID: 24385510
2. Calabresi L, Rossoni G, Gomaraschi M, Sisto F, Berti F, Franceschini G. High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factoralpha content and enhancing prostaglandin release. Circulation research. 2003; 92(3):330-7. Epub 2003/02/22. PMID: 12595346
3. Theilmeier G, Schmidt C, Herrmann J, Keul P, Schafers M, Herrgott I, et al. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation. 2006; 114(13):1403-9. Epub 2006/09/20. doi: 10.1161/CIRCULATIONAHA.105.607135 PMID: 16982942
4. Rossoni G, Gomaraschi M, Berti F, Sirtori CR, Franceschini G, Calabresi L. Synthetic high-density lipoproteins exert cardioprotective effects in myocardial ischemia/reperfusion injury. The Journal of pharmacology and experimental therapeutics. 2004; 308(1):79-84. Epub 2003/10/21. doi: 10.1124/jpet.103.057141 PMID: 14566009
5. Marchesi M, Booth EA, Davis T, Bisgaier CL, Lucchesi BR. Apolipoprotein A-IMilano and 1-palmitoyl-2-oleoyl phosphatidylcholine complex (ETC-216) protects the in vivo rabbit heart from regional ischemiareperfusion injury. The Journal of pharmacology and experimental therapeutics. 2004; 311(3):1023-31. Epub 2004/09/18. doi: 10.1124/jpet.104.070789 PMID: 15375174
6. Sattler KJ, Elbasan S, Keul P, Elter-Schulz M, Bode C, Graler MH, et al. Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease. Basic research in cardiology. 2010; 105 (6):821-32. Epub 2010/07/24. doi: 10.1007/s00395-010-0112-5 PMID: 20652276
7. Sattler K, Lehmann I, Graler M, Brocker-Preuss M, Erbel R, Heusch G, et al. HDL-Bound Sphingosine 1-Phosphate (S1P) Predicts the Severity of Coronary Artery Atherosclerosis. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology. 2014; 34(1):172-84. Epub 2014/07/01. doi: 10.1159/000362993.
8. James RW, Proudfoot A, Pometta D. Immunoaffinity fractionation of high-density lipoprotein subclasses 2 and 3 using anti-apolipoprotein A-I and A-II immunosorbent gels. Biochimica et biophysica acta. 1989; 1002(3):292-301. Epub 1989/04/26. PMID: 2469471
9. Jonas A. Reconstitution of high-density lipoproteins. Methods in enzymology. 1986; 128:553-82. Epub 1986/01/01. PMID: 3724523
10. Frias MA, Somers S, Gerber-Wicht C, Opie LH, Lecour S, Lang U. The PGE2-Stat3 interaction in doxorubicin-induced myocardial apoptosis. Cardiovascular research. 2008; 80(1):69-77. Epub 2008/06/24. doi: 10.1093/cvr/cvn171 PMID: 18567640
11. Smith RM, Suleman N, McCarthy J, Sack MN. Classic ischemic but not pharmacologic preconditioning is abrogated following genetic ablation of the TNFalpha gene. Cardiovascular research. 2002; 55 (3):553-60. Epub 2002/08/06. PMID: 12160952
12. Braunersreuther V, Pellieux C, Pelli G, Burger F, Steffens S, Montessuit C, et al. Chemokine CCL5/RANTES inhibition reduces myocardial reperfusion injury in atherosclerotic mice. Journal of molecular and cellular cardiology. 2010; 48(4):789-98. Epub 2009/08/12. doi: 10.1016/j.yjmcc.2009.07.029 PMID: 19665464
13. Montecucco F, Bauer I, Braunersreuther V, Bruzzone S, Akhmedov A, Luscher TF, et al. Inhibition of nicotinamide phosphoribosyltransferase reduces neutrophil-mediated injury in myocardial infarction. Antioxidants & redox signaling. 2013; 18(6):630-41. Epub 2012/03/29. doi: 10.1089/ars.2011.4487.
14. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. The New England journal of medicine. 2007; 357 (21):2109-22. Epub 2007/11/07. doi: 10.1056/NEJMoa0706628 PMID: 17984165
15. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA: the journal of the American Medical Association. 2003; 290(17):2292-300. Epub 2003/11/06. doi: 10.1001/jama.290.17.2292 PMID: 14600188
16. Patel S, Drew BG, Nakhla S, Duffy SJ, Murphy AJ, Barter PJ, et al. Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. Journal of the American College of Cardiology. 2009; 53 (11):962-71. Epub 2009/03/14. doi: 10.1016/j.jacc.2008.12.008 PMID: 19281927
17. Tardif JC, Gregoire J, L'Allier PL, Ibrahim R, Lesperance J, Heinonen TM, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA: the journal of the American Medical Association. 2007; 297(15):1675-82. Epub 2007/03/28. doi: 10.1001/jama.297.15.jpc70004 PMID: 17387133
18. Shaw JA, Bobik A, Murphy A, Kanellakis P, Blombery P, Mukhamedova N, et al. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circulation research. 2008; 103(10):1084-91. Epub 2008/10/04. doi: 10.1161/CIRCRESAHA.108.182063 PMID: 18832751
19. Nieuwdorp M, Vergeer M, Bisoendial RJ, op 't Roodt J, Levels H, Birjmohun RS, et al. Reconstituted HDL infusion restores endothelial function in patients with type 2 diabetes mellitus. Diabetologia. 2008; 51(6):1081-4. Epub 2008/04/05. doi: 10.1007/s00125-008-0975-2 PMID: 18389214
20. Drew BG, Duffy SJ, Formosa MF, Natoli AK, Henstridge DC, Penfold SA, et al. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation. 2009; 119 (15):2103-11. Epub 2009/04/08. doi: 10.1161/CIRCULATIONAHA.108.843219 PMID: 19349317
21. Chenevard R, Hurlimann D, Spieker L, Bechir M, Enseleit F, Hermann M, et al. Reconstituted HDL in acute coronary syndromes. Cardiovascular therapeutics. 2012; 30(2):e51-7. Epub 2010/09/16. doi: 10.1111/j.1755-5922.2010.00221.x PMID: 20840194
22. Marchesi M, Booth EA, Rossoni G, Garcia RA, Hill KR, Sirtori CR, et al. Apolipoprotein A-IMilano/POPC complex attenuates post-ischemic ventricular dysfunction in the isolated rabbit heart. Atherosclerosis. 2008; 197(2):572-8. Epub 2007/10/20. doi: 10.1016/j.atherosclerosis.2007.08.028 PMID: 17945238
23. Kiya Y, Miura S, Imaizumi S, Uehara Y, Matsuo Y, Abe S, et al. Reconstituted high-density lipoprotein attenuates postinfarction left ventricular remodeling in rats. Atherosclerosis. 2009; 203(1):137-44. Epub 2008/07/09. doi: 10.1016/j.atherosclerosis.2008.05.056 PMID: 18606412
24. Sutter I, Park R, Othman A, Rohrer L, Hornemann T, Stoffel M, et al. Apolipoprotein M modulates erythrocyte efflux and tubular reabsorption of sphingosine-1-phosphate. Journal of lipid research. 2014; 55 (8):1730-7. Epub 2014/06/22. doi: 10.1194/jlr.M050021 PMID: 24950692
25. Tao R, Hoover HE, Honbo N, Kalinowski M, Alano CC, Karliner JS, et al. High-density lipoprotein determines adult mouse cardiomyocyte fate after hypoxia-reoxygenation through lipoprotein-associated sphingosine 1-phosphate. American journal of physiology Heart and circulatory physiology. 2010; 298 (3):H1022-8. Epub 2010/01/12. doi: 10.1152/ajpheart.00902.2009 PMID: 20061542
26. Frias MA, Lang U, Gerber-Wicht C, James RW. Native and reconstituted HDL protect cardiomyocytes from doxorubicin-induced apoptosis. Cardiovascular research. 2010; 85(1):118-26. Epub 2009/08/25. doi: 10.1093/cvr/cvp289 PMID: 19700468
27. Frias MA, Pedretti S, Hacking D, Somers S, Lacerda L, Opie LH, et al. HDL protects against ischemia reperfusion injury by preserving mitochondrial integrity. Atherosclerosis. 2013; 228(1):110- 6. Epub 2013/03/19. doi: 10.1016/j.atherosclerosis.2013.02.003 PMID: 23497785
28. Somers SJ, Frias M, Lacerda L, Opie LH, Lecour S. Interplay between SAFE and RISK pathways in sphingosine-1-phosphate-induced cardioprotection. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy. 2012; 26(3):227-37. Epub 2012/03/07. doi: 10.1007/s10557-012-6376-2 PMID: 22392184